AGIO News Alert Agios Pharmaceuticals Inc (AGIO) 48.91 09/19/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2014 at 5:41 PM

Agios Pharmaceuticals Inc (AGIO) 48.91 $AGIO

Strong On High Relative Volume: Agios Pharmaceuticals (AGIO)
at The Street - Fri Sep 19, 9:04AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a strong on high relative volume candidate

Jim Cramer's Top Stock Picks: AGIO AAPL LUV
at The Street - Wed Sep 17, 5:00AM CDT
Cramer says the charts predict a rally soon for Apple stock while Southwest remains his favorite airline.

Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.

Agios Pharmaceuticals (AGIO): Today's Weak On High Volume Stock
at The Street - Fri Sep 12, 9:08AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Tue Aug 12, 12:38PM CDT
Levi & Korsinsky, LLP is investigating Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.

Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 6:30AM CDT
- AG-221: Company on track to start four Phase 1 expansion cohorts in second half of 2014; abstract of additional Phase 1 data submitted to the 2014 ASH Annual Meeting -

Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Mon Jul 28, 8:00AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will host a conference call and live webcast on Thursday, August 7, 2014 at 8:30 a.m. EDT to report its second quarter 2014 financial results and discuss recent business activities.

Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.

Orphan Drug Designations, Financial Results, Board Elections, and Raised Financial Guidance - Analyst Notes on Agios, Alder, Healthways, NeoGenomics and Sequenom
PR Newswire - Wed Jul 02, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Healthways Inc. (NASDAQ: HWAY), NeoGenomics Inc. (NASDAQ: NEO) and Sequenom Inc. (NASDAQ: SQNM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4351-100free.

5 Stocks With Big Insider Buying
at The Street - Wed Jun 25, 11:53AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.

Nasdaq stocks posting largest percentage decreases
AP - Tue Jun 24, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Agios Presents Data on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 4:21PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced new clinical data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies.

2 Surging Biotechs with Links to Celgene
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 16, 1:03PM CDT
Celgene is sharing its experience and opening its wallet to a slate of fledgling biotech companies in a bid to lock-up the next generation of game-changing therapies. Agios and bluebird bio are two of those companies and each reported news...

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia
Business Wire - Mon Jun 16, 7:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia (AML). AG-221 is an oral, first-in-class IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.

3 Stocks Rising on Unusual Volume
at The Street - Mon Jun 16, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.

New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies
Business Wire - Sat Jun 14, 6:31AM CDT
--Agios Pharmaceuticals to Host Investor Webcast on June 16, 2014 at 8:30 a.m. EDT

Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration
Business Wire - Fri Jun 13, 7:03AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that its partner Celgene Corporation has exercised its option to an exclusive worldwide license to AG-221, an oral, first-in-class, potent inhibitor of the mutant IDH2 protein. Under the terms of the agreement, the option to license extended to Celgene through the end of Phase 1, but AG-221 has been exercised early based on the Phase 1 data generated to date. AG-221 is currently in a Phase 1 dose escalation study in patients that harbor an IDH2 mutation with advanced hematologic malignancies, including acute myeloid leukemia (AML).

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

Dar Global Eyes Dubai for Strategic Real Estate Moves

Tapping into Dubai's Real Estate Allure Every seasoned investor knows the real estate game ain't for the faint of heart, especially when you’re playing in a market as competitive as Dubai's. But here comes Dar Global Capital Partners (DGCP), throwing their hat into the ring with a fresh strategy centered around high-value real estate. Sure, they aren't new to the...

Ouma Connect Streamlines Surrogacy Medical Clearance

A Game Changer for Surrogacy Agencies When we talk about innovation, we often focus on the flashiest tech in finance or the buzz of a scorching hot stock. But here's Ouma Health, shifting gears in a sector many traders don't blink at—surrogacy. They're unveiling Ouma Connect, a portal pulling back the curtain on medical clearances for gestational-carrier candidates....

Parloa's AI Agents Boost SAP Customer Experience

AI Meets SAP in Customer Experience Revolution Alright, let's cut through the tech chatter. Parloa’s Agent Management Platform has hitched its wagon to SAP as a spiffy Solution Extension. This isn't just tech fluff—it’s a big step for scratching that CX itch companies have. By merging Parloa's AI magic with SAP's existing mojo, businesses get a toolset to enhance...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Clarins Dazzles Austin with Skin Longevity Event

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

AVANT BIO Beef Up Team with Heavyweights Lio, Vanek

AVANT BIO's Latest Power Play Alright, here's a big splash in the gene pool of life sciences—AVANT BIO just drafted two industry veterans, Peggy Lio and Philip Vanek, into their Operating Advisor Hall of Fame. And these folks aren't just window dressing. They're packing experience from some of the big hitters like GE Healthcare and Lonza, ready to roll up their sleeves...

HONOR X9e Pro Unveils with Massive Battery Power

Lighting Up the Sky: HONOR's Big Move Picture this: the Burj Khalifa in Dubai, world’s tallest building, flashing with the promise of a smartphone's monstrous battery. That’s what the fine folks at HONOR did, highlighting their X9e Pro and its mind-boggling 11,000mAh battery. Now, am I the only one who finds it more than a little audacious to leverage such a flashy...